Ten years' experience with Haemophilus influenzae type b (Hib) conjugate vaccines in Finland

Reviews and Research in Medical Microbiology

Volumn 7, Issue 4, 1996, Pages 231-241

  Eskola, Juhani ^a   Käyhty, Helena ^a  

^a NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

Author keywords

Conjugate; Haemophilus influenzae; Hib; Vaccines

Indexed keywords

HAEMOPHILUS INFLUENZAE TYPE B VACCINE;

BACTEREMIA; BACTERIAL MENINGITIS; CLINICAL TRIAL; DRUG EFFICACY; FINLAND; GRAM NEGATIVE INFECTION; HAEMOPHILUS INFLUENZAE TYPE B; HUMAN; IMMUNIZATION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; PRIORITY JOURNAL; REVIEW; VACCINATION;

EID: 0029803044     PISSN: 0954139X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00013542-199610000-00005     Document Type: Review

References (55)

1. Saarinen M, Takala AK, Koskenniemi E et al. Spectrum of 2836 cases of pediatric invasive infections: results of a prospective nationwide 5-year surveillance in Finland. Clin Infect Dis 1995; 21: 1134-1144.
2. Vadheim CM, Ward JI. Epidemiology in developed countries. In: Ellis R and Granoff DM, eds. Development and clinical uses of Haemophilus b conjugate vaccines. New York: Marcel Decker, 1994; 231-245.
3. Takala AK, Eskola J, Peltola H, Mäkelä PH. Epidemiology of invasive Haemophilus influenzae type b disease among children in Finland before vaccination with Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 1989; 8: 297-302.
4. Fothergill L, Wright J. Relation of age incidence to the bactericidal power of blood against the causal organism. J Immunol 1933; 24: 273-284.
5. Peltola H, Käyhry H, Virtanen M, Mäkelä PH. Prevention of Haemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine. N Engl J Med 1984; 310: 1566-1569.
6. Santosham M, Reid R, Ambrosino DM et al. Prevention of Haemophilus influenzae type b infections in high-risk infants treated with bacterial polysaccharide immune globulin. N Engl J Med 1987; 317: 923-929.
7. Ambrosino DM, Landesman SH, Gorham CC, Siber GR. Passive immunization against disease due to Haemophilus influenzae type b: concentrations of antibody to capsular polysaccharide in high-risk children. J Infect Dis 1986; 153: 1-7.
8. Peltola H, Käyhty H, Sivonen A. Haemophilus influenzae type b capsular polysaccharide vaccine in children: a double-blind field trial of 100000 vaccinees 3 months to 5 years of age in Finland. Pediatrics 1977; 60: 730-737.
9. Käyhty H, Peltola H, Karanko V et al. The protective level of serum antibodies to the capsular polysaccharide of a Haemophilus influenzae type b. J Infect Dis 1983; 147: 1100.
10. Mosier DE, Subbarao B. Thymus-independent antigens: complexity of B-lymphocyte activation revealed. Immunology 1982; 3: 217-222.
11. Käyhty H, Karanko V, Peltola H, Mäkelä PH. Serum antibodies after vaccination with Haemophilus influenzae type b capsular polysaccharide and responses to reimmunization: no evidence of immunologic tolerance or memory. Pediatrics 1984; 74: 857-865.
12. Käyhty H, Eskola J, Peltola H, Stout MG, Samuelson JS, Gordon LK. Immunogenicity in infants of a vaccine composed of Haemophilus influenzae type b capsular polysaccharide mixed with DTP or conjugated to diphtheria toxoid. J Infect Dis 1987; 155: 100-106.
13. Avery OT, Goebel WF. Chemo-immunological studies on conjugated carbohydrate-proteins. II. Immunological specificity of synthetic sugar-protein antigens. J Exp Med 1929; 50: 533-550.
14. Schneerson R, Barrera O, Sutton A, Robbins J. Preparation, characterization, and immunogenicity of Haemophilus influenzae type b polysaccharide-protein conjugates. J Exp Med 1980; 152: 361-376.
15. Eskola J, Käyhty H, Peltola H et al. Antibody levels achieved in infants by course of Haemophilus influenzae type b polysaccharide/diphtheria toxoid conjugate vaccine. Lancet 1985; i: 1184-1186.
16. Insel R, Anderson P. Oligosaccharide-protein conjugate vaccines induce and prime for oligoclonal IgG antibody responses to the Haemophilus influenzae b capsular polysaccharide in human infants. J Exp Med 1986; 163: 262-269.
17. Käyhty H, Eskola J, Peltola H, Saarinen L, Mäkelä PH. High antibody responses to booster doses of either Haemophilus influenzae type b capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccine. J. Infect Dis 1992; 165 (Suppl.): 165-166.
18. Käyhty H, Saarinen L, Rönnberg P-R, Tillikainen R, Eskola J. Long term persistence of immunity evoked by Hib conjugate vaccine. 35th Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, California. 17-20 September 1995.
19. Daum RS, Granoff DM. Lessons from the evaluation of immunogenicity. In: Ellis R and Granoff DM, eds. Development and clinical uses of Haemophilus b conjugate vaccines. New York: Marcel Decker, 1994; 291-312.
20. Dintzis RZ. Rational design of conjugate vaccines. Ped Res 1992; 32: 376-385.
21. Donnelly JJ, Liu MA. Immunobiology of protein carriers. In: Ellis R and Granoff DM, eds. Development and clinical uses of Haemophilus b conjugate vaccines. New York: Marcel Decker, 1994; 71-90.
22. Eskola J, Peltola H, Takala AK et al. Efficacy of Haemophilus influenzae type b polysaccharide-diphtheria toxoid conjugate vaccine in infancy. N Engl J Med 1987; 317: 717-722.
23. Eskola J, Käyhty H, Takala AK et al. A randomized prospective field trial of a conjugate vaccine in the protection of infants and young children against invasive Haemophilus influenzae type b disease. N Engl J Med 1990; 323: 1381-1387.
24. Peltola H, Eskola J, Käyhty H, Takala AK, Mäkelä PH. Clinical comparison of the Haemophilus influenzae type polysaccharide-diphtheria toxoid vs. the oligosaccharide CRM197 protein vaccines in infancy. Arch Pediatr Adolesc Med 1994; 148: 620-625.
25. Black SB, Shinefield HR, Fireman B et al. Efficacy in infancy of oligosaccharide conjugate Haemophilus influenzae type b (HbOC) vaccine in a United States population of 61080 children. Pediatr Infect Dis J 1991; 10: 97-104.
26. Santosham M, Wolff M, Reid R et al. The efficacy in Navajo infants of a conjugate vaccine consisting of Haemophilus influenzae type b polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 1991; 324: 1767-1772.
27. Booy R, Moxon ER, MacFarlane JA, Mayon-White RT, Slack MPE. Efficacy of Haemophilus influenzae type b conjugate vaccines in Oxford region. Lancet 1992; 340: 847.
28. Vadheim C, Greenberg D, Partridge S et al. Effectiveness and safety of an Haemophilus influenzae type b conjugate vaccine (PRP-T) in young infants. Pediatrics 1993; 92: 272-279.
29. Ward J, Brenneman G, Letson GW, Heyward WL, the Alaska H. influenzae Vaccine Study Group. Limited efficacy of a Haemophilus influenzae type b conjugate vaccine in Alaska Native infants. N Engl J Med 1990; 323: 1393-1401.
30. Granhoff DM, Holmes SJ, Osterholm MT et al. Induction of immunologic memory in infants primed with Haemophilus influenzae type b conjugate vaccines. J Infect Dis 1993; 168: 663-671.
31. Käyhty H. Difficulties in establishing a serological correlate of protection after immunization with Haemophilus influenzae conjugate vaccines. Biologicals 1994; 22: 397-402.
32. Peltola H, Kilpi T, Anttila M. Rapid disappearance of Haemophilus influenzae type b meningitis after routine childhood immunisation with conjugate vaccines. Lancet 1992; 340: 592-594.
33. Takala AK, Peltola H, Eskola J. Disappearance of epiglottitis during large-scale vaccination with Haemophilus influenzae type b conjugate vaccine among children in Finland. Laryngoscope 1994; 104: 731-735.
34. Eskola J, Takala AK, Käyhty H et al. Protection achieved by Haemophilus influenzae type b (Hib) conjugate vaccines is better than expected on the basis of efficacy trials. Programs and Abstracts of the 32rd ICAAC, Anaheim, CA, 1992: 273.
35. Takala AK, Eskola J, Leinonen M et al. Reduction of oropharyngeal carriage of the Haemophilus influenzae type b (Hib) in children immunised with an Hib conjugate vaccine. J Infect Dis 1991; 164: 982-986.
36. Harbour ML, Mayon-White RT, Coles C, Crook DWM, Moxon ER. The impact of conjugate vaccine on carriage on Haemophilus influenzae type b. J Infect Dis 1995; 171: 93-98.
37. Mohle-Boetani J, Ajello G, Breneman E et al. Carriage of Haemophilus influenzae type b in children after widespread vaccination with conjugate Haemophilus influenzae. Pediatr Infect Dis J 1993; 12: 589-593.
38. Murphy TV, Pastor P, Medley F, Osterholm T, Granoff DM. Decreased Haemophilus colonization in children vaccinated with Haemophilus influenzae type b conjugate vaccine. J Pediatr 1993; 122: 517-523.
39. Takala AK, Santosham S, Almeido-Hill BS et al. Vaccination with Haemophilus influenzae type b meningococcal protein conjugate vaccine reduces oropharyngeal carriage of Haemophilus influenzae type b among American Indian children. Pediatr Infect Dis J 1994; 12: 593-599.
40. Kauppi M, Saarinen L, Käyhty H. Anti-capsular polysaccharide antibodies reduce nasopharyngeal colonization by Haemophilus influenzae type b in infant rats. J Infect Dis 1993; 167: 365-371.
41. Kauppi M, Eskola J, Käyhty H. Anti-capsular polysaccharide antibody concentrations in saliva after immunization with Haemophilus influenzae type b conjugate vaccine. Pediatr Infect Dis J 1995; 14: 286-294.
42. Kurikka S. Priming with diphtheria-tetanus-pertussis vaccine enhances the response to the Haemophilus influenzae type b tetanus conjugate vaccine in infancy. Vaccine 1996 (in press).
43. Kurikka S, Käyhty H, Peltola H, Saarinen L, Eskola J, Mäkelä PH. Neonatal immunization: Response to Haemophilus influenzae type b-tetanus toxoid conjugate vaccine. Pediatrics 1995; 95: 815-822.
44. Kurikka S, Käyhty H, Saarinen L, Rönnberg P-R, Eskola J, Mäkelä PH. Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy. J Infect Dis 1996; 172: 1268-1272.
45. Gordon LK. Characterization of a hapten-carrier conjugate vaccine: H. influenzae-diphtheria conjugate vaccine. In: Chancock RM and Lerner RA, eds. Cold Spring Harbor, NY: Cold Spring Harbor Laboratory, 1984; 393-396.
46. Lise LD, Mazier D, Jolivet M et al. Enhanced epitopic response to a synthetic human malarial peptide by preimmunization with tetanus toxoid carrier. Infect Immun 1987; 55: 2658-2661.
47. Herzenberg LA, Tokuhisa T, Heraenberg LA. Carrier priming leads to hapten-specific suppression. Nature 1980; 285: 665-667.
48. Insel RA. Potential alterations in immunogenicity by combining or simultaneously administering vaccine components. Ann NY Acad Sci 1995; 754: 35-47.
49. Eskola J. Combined vaccines consisting of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis vaccines. J Infect Dis 1996 (in press).
50. Eskola J, Ölander R-M, Litmanen L, Saarinen L, Bogaerts H, Käyhty H. Hib antibody response after two doses of combined DTPa-Hib conjugate vaccine as compared to separate injections. 35th Interscience Congress on Antimicrobial Agents and Chemotherapy (ICAAC). San Francisco, California. 17-20 September 1995.
51. Clements DA, Booy R, Dagan R et al. Comparison of the epidemiology and cost of Haemophilus influenzae type b disease in five western countries. Pediatr Infect Dis J 1993; 12: 362-367.
52. Bijlmer HA. Epidemiology of Haemophilus influenzae invasive disease in developing countries and intervention strategies. In: Ellis R and Granoff DM, eds. Development and clinical uses of Haemophilus b conjugate vaccines. New York: Marcel Decker, 1994; 247-264.
53. Mulholland K, Ahonkhai VI, Greenwood AM et al. Safety and immunogenicity of Haemophilus influenzae type b-Neisseria meningitidis group b outer membrane protein complex conjugate vaccine mixed in the syringe with diphtheria-tetanus-pertussis vaccine in young Gambian infants. Pediatr Infect Dis J 1993; 12: 632-637.
54. Capeding RZ, Nohynek H, Pascual LG et al. Immunogenicity of three Haemophilus influenzae type b conjugate vaccines after a primary vaccination series in Filippino infants. Am J Tropical Med 1996; (in press).
55. Mäkelä PH, Eskola J, Käyhty H, Takala AK. Vaccines against Haemophilus influenzae type b. In: Ala-Aldeen D, Hormaeche C, eds. Molecular and clinical aspects of bacterial vaccine development. John Wiley, 1995; 41-91.